ME02016B - Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola - Google Patents

Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola

Info

Publication number
ME02016B
ME02016B MEP-2015-9A MEP915A ME02016B ME 02016 B ME02016 B ME 02016B ME P915 A MEP915 A ME P915A ME 02016 B ME02016 B ME 02016B
Authority
ME
Montenegro
Prior art keywords
dioxabicyclo
chloro
hydroxymethyl
phenyl
compound
Prior art date
Application number
MEP-2015-9A
Other languages
English (en)
Inventor
Vincent Mascitti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ME02016B publication Critical patent/ME02016B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Spoj Formule (A) ili Formule (B)naznačen time štoR je -OH ili, kada je R1 -O-C(O)-(C1-C4)alkil ili -O-C(O)-aril, R je isti kao R1 ili -OH;R1 je -OH, F, Cl, -O-C(O)-(C1-C4)alkil, -O-C(O)-aril, -O-C(O)-O-(C1-C4)alkil ili -O-C(O)-O-aril; iR2 je -OH, -O-(C1-C4)alkil ili -O-CH2-CH2-O-R2a; uz uvjet da kada je R -OH, a R1 je -OH, R2 je -OH ili -O-CH2-CH2-O-R2a;R2a je H, -C(O)-(C1-C4)alkil, -C(O)-aril, -C(O)-O-(C1-C4)alkil ili -C(O)-O-aril;i njihove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj spoj Formule (A).
3. Spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je R1 -OH.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R2 -OH.
5. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R2 -O-CH2CH2OH.
6. Spoj, naznačen time što ga se bira iz skupine koju čine: (1R,2S,3S,4R,5S)-3,4-diacetoksi-1-acetoksimetil-5-[4-klor-3-(4-etoksibenzil)fenil]-6,8-dioksabiciklo[3.2.1]okt-2-ilni ester octene kiseline; (1R,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-2,3,4-trihidroksi-6,8-dioksabiciklo[3.2.1]okt-1-ilmetilni ester octene kiseline; (1R,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-2,3,4-trihidroksi-6,8-dioksabiciklo[3.2.1]okt-1-ilmetilni ester etilni ester ugljične kiseline; (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-[D5]etoksibenzil)fenil]-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; 2-{4-[2-klor-5-((1S,2S,3S,4R,5S)-2,3,4-trihidroksi-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]okt-5-il)benzil]fenoksi}etilni ester octene kiseline; (1S,2S,3S,4R,5S)-5-{4-klor-3-[4-(2-hidroksietoksi)benzil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; i (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-etoksibenzil)fenil]-1-fluormetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; ili njihove farmaceutski prihvatljive soli.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je navedeni spoj (1S,2S,3S,4R,5S)-5-[4-klor-3-(4-hidroksibenzil)fenil]-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol.
8. Spoj, naznačen time što ga se bira iz skupine koju čine: (1S,2S,3S,4R,5S)-5-{4-klor-3-[(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; (1S,2S,3S,4R,5S)-5-{4-klor-3-[(R)-(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol; i (1S,2S,3S,4R,5S)-5-{4-klor-3-[(S)-(4-etoksifenil)hidroksimetil]fenil}-1-hidroksimetil-6,8-dioksabiciklo[3.2.1]oktan-2,3,4-triol.
9. Farmaceutski pripravak, naznačen time što sadrži: (i) spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegovu farmaceutski prihvatljivu sol; i (ii) farmaceutski prihvatljivu pomoćni tvar, razrjeđivač, ili podlogu.
10. Pripravak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni spoj, ili navedena njegova terapijski prihvatljiva sol, prisutan u terapijski djelotvornoj količini.
11. Pripravak u skladu s patentnim zahtjevima 9 ili 10, naznačen time što dodatno sadrži najmanje jedno dodatno farmaceutsko sredstvo, koje se bira iz skupine koju čine sredstvo protiv pretilosti i antidijabetično sredstvo.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeno sredstvo protiv pretilosti se bira iz skupine koju čine rimonabant, taranabant, surinabant, otenabant, SLV319 (CAS No. 464213-10-3), AVE1625 (CAS No. 358970-97-5)), dirlotapid, mitratapid, implitapid, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorkaserin, cetilistat, PYY3-36, naltrekson, oleoil-estron, obinepitid, pramlintid, tesofenzin, leptin, liraglutid, bromokriptin, orlistat, eksenatid, AOD-9604 (CAS No. 221231-10-3) i sibutramin.
13. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeni antidijabetično sredstvo se bira iz skupine koju čine metformin, acetoheksamid, klorpropamid, Diabinese, glibenklamid, glipizid, gliburid, glimepirid, gliklazid, glipentid, glikidon, glizolamid, tolazamid, tolbutamid, tendamistat, trestatin, akarboza, adipozin, kamigliboza, emiglitat, miglitol, vogliboza, pradimicin-Q, salbostatin, balaglitazon, ciglitazon, darglitazon, englitazon, isaglitazon, pioglitazon, rosiglitazon, troglitazon, eksendin-3, eksendin-4, liraglutid, troduskvemin, rezveratrol, hirtiosalni ekstrakt, sitagliptin, vildagliptin, alogliptin i saksagliptin.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 9 do 13, naznačen time što je namijenjen upotrebi u liječenju pretilosti i poremećaja povezanih s pretilošću kod životinja.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 9 do 13, naznačen time što je namijenjen upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa tip 2 i poremećaja povezanih s dijabetesom kod životinja. Pfizer Inc. Zastupani po:
MEP-2015-9A 2009-11-02 2010-10-21 Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola ME02016B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25714009P 2009-11-02 2009-11-02
US37293810P 2010-08-12 2010-08-12
EP10776433.4A EP2496583B1 (en) 2009-11-02 2010-10-21 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
PCT/IB2010/054775 WO2011051864A1 (en) 2009-11-02 2010-10-21 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Publications (1)

Publication Number Publication Date
ME02016B true ME02016B (me) 2015-05-20

Family

ID=43297093

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-9A ME02016B (me) 2009-11-02 2010-10-21 Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola

Country Status (22)

Country Link
US (5) US8669380B2 (me)
EP (1) EP2496583B1 (me)
JP (1) JP5696156B2 (me)
KR (1) KR101426180B1 (me)
AP (1) AP3099A (me)
AU (1) AU2010310956B2 (me)
CA (1) CA2777857C (me)
CR (1) CR20120289A (me)
DK (1) DK2496583T3 (me)
EA (1) EA021983B1 (me)
EC (1) ECSP12011946A (me)
ES (1) ES2527179T3 (me)
GE (1) GEP20146104B (me)
HR (1) HRP20150107T1 (me)
ME (1) ME02016B (me)
NZ (1) NZ599945A (me)
PL (1) PL2496583T3 (me)
PT (1) PT2496583E (me)
RS (1) RS53827B1 (me)
SI (1) SI2496583T1 (me)
WO (1) WO2011051864A1 (me)
ZA (1) ZA201203486B (me)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012163546A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2717689A4 (en) * 2011-06-13 2014-11-05 Panacea Biotec Ltd NEW SGLT HEMMER
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP3466431B1 (en) * 2013-03-14 2023-11-15 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
CN104619713B (zh) * 2013-05-24 2017-06-16 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2015027963A1 (zh) * 2013-09-02 2015-03-05 四川海思科制药有限公司 芳环类衍生物、其药物组合物及其应用
ES2605886T3 (es) 2013-09-27 2017-03-16 Sunshine Lake Pharma Co., Ltd. Derivados de glucopiranosilo y sus usos en medicina
PL3145934T3 (pl) 2014-05-19 2021-08-16 Pfizer Inc. Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
CN105461762B (zh) * 2014-09-27 2018-12-04 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
US9579288B2 (en) 2015-03-03 2017-02-28 Saniona A/S Tesofensine and beta blocker combination formulations
CN105646603A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型a及制备方法
CN105646604A (zh) * 2016-03-01 2016-06-08 孙霖 埃格列净晶型b及制备方法
CN107382952B (zh) * 2017-07-13 2020-02-28 杭州科巢生物科技有限公司 埃格列净的制备方法及其中间体
CN107857768A (zh) * 2018-01-04 2018-03-30 威海贯标信息科技有限公司 一种埃格列净新晶型
WO2020026273A1 (en) * 2018-07-31 2020-02-06 Msn Laboratories Private Limited, R&D Center Solid forms of ertugliflozin free base and solid dispersions comprising ertugliflozin l-pyroglutamic acid.
CN111269241A (zh) * 2018-12-05 2020-06-12 广西久福生物科技有限公司 一种新型化合物及其制备方法与应用
WO2021137144A1 (en) * 2019-12-31 2021-07-08 Hikal Limited An efficient process for the preparation of ertugliflozin l-pyroglutamic acid and intermediates thereof
CN113214263B (zh) * 2020-02-06 2022-09-30 北京桦冠医药科技有限公司 瑞德西韦关键中间体的一种合成方法
CN117624265A (zh) * 2023-11-27 2024-03-01 江苏海悦康医药科技有限公司 艾托格列净杂质的合成方法

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5373598A (en) * 1976-12-11 1978-06-30 Teikoku Chem Ind Corp Ltd Saccharide derivatives and process for thir preparation
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
JPS5911600B2 (ja) * 1981-04-30 1984-03-16 理化学研究所 ３−アジド−１，６−アンヒドロ−３−デオキシ−２，４−ジ−Ｏ−ベンジル−β−Ｄ−グルコピラノ−ス及びその製造法
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4590201A (en) 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
NZ214774A (en) 1986-01-08 1989-10-27 Nz Scientific & Ind Res Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives
DE3750182T2 (de) 1986-10-30 1994-11-10 Terumo Corp (alpha)-HYDROPEROXYISOPROPYLPHENYL-VERBINDUNGEN UND VERFAHREN ZUR HERSTELLUNG.
US5041541A (en) 1988-05-05 1991-08-20 The Procter & Gamble Company Functional sugar substituted with reduced calories
WO1991009537A1 (en) 1989-12-21 1991-07-11 The Procter & Gamble Company Food compositions containing reduced calorie fats and reduced calorie sugars
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
AU2753292A (en) 1991-10-04 1993-05-03 Procter & Gamble Company, The Cholesterol lowering compounds and process for making them
CA2079544A1 (en) 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
PT850948E (pt) 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
CA2283636A1 (en) 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2001042469A1 (en) 1999-12-10 2001-06-14 Lexicon Genetics Incorporated Novel human transporter protein and polynucleotides encoding the same
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
WO2001057214A2 (en) 2000-02-03 2001-08-09 Lexicon Genetics Incorporated Human transporter proteins and polynucleotides encoding the same
DE10006887A1 (de) 2000-02-16 2001-09-06 Hermann Koepsell Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
SK287811B6 (sk) 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
ES2337127T3 (es) 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
EP1344780A4 (en) 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
US20020081678A1 (en) 2000-12-11 2002-06-27 Gennady Merkulov Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002053738A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Nouvelles proteines et adn correspondant
ATE431830T1 (de) 2000-12-28 2009-06-15 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP4147111B2 (ja) 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2442651A1 (en) 2001-03-27 2002-10-17 Pe Corporation (Ny) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
CN100577175C (zh) 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
AU2002338643A1 (en) 2001-04-10 2002-10-28 Millennium Pharmaceuticals, Inc. 68723, sodium/glucose cotransporter family members and uses therefor
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
JP4399251B2 (ja) 2001-05-30 2010-01-13 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
AU2002358469A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Modified receptors for the discovery of therapeutic ligands
WO2003056329A2 (en) 2001-12-21 2003-07-10 7Tm Pharma A/S Use of a signal transduction complex in drug discovery processes
AU2002367140A1 (en) 2001-12-27 2003-07-15 Takeda Chemical Industries, Ltd. Human sglt homolog promoter and use thereof
DE10212557A1 (de) 2002-03-14 2003-09-25 Univ Schiller Jena Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens
MXPA04009229A (es) 2002-03-22 2004-11-26 Kissei Pharmaceutical Cristales derivados de glucopiranosiloxibencil benceno.
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE10225844A1 (de) 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
RU2356906C2 (ru) 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
RU2322449C2 (ru) 2002-08-09 2008-04-20 Тайсо Фармасьютикал Ко., Лтд. ПРОИЗВОДНЫЕ АРИЛ 5-ТИО-β-D-ГЛЮКОПИРАНОЗИДА И ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА ПРИ ДИАБЕТЕ, СОДЕРЖАЩИЕ ИХ
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
WO2004039405A1 (ja) 2002-10-29 2004-05-13 Takeda Pharmaceutical Company Limited Ｓｇｌｔホモログ用途
US20060035844A1 (en) 2002-12-04 2006-02-16 Fumiaki Ito Preventive or remedy for diseases caused by hyperglycemia
JP4651934B2 (ja) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP4679155B2 (ja) 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
JP2006516257A (ja) 2003-01-03 2006-06-29 ブリストル−マイヤーズ　スクイブ　カンパニー Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法
CN1771334A (zh) 2003-03-07 2006-05-10 施瑞修德制药公司 用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法
ES2363941T3 (es) 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
EP1609799A4 (en) 2003-04-01 2008-10-29 Taisho Pharmaceutical Co Ltd HETEROARYL-5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND AGENTS AGAINST DIABETES THEREOF
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004093544A1 (ja) 2003-04-24 2004-11-04 Ishihara Sangyo Kaisha, Ltd. 置換ベンゼン誘導体又はその塩、それらの製造方法、並びにそれらを有効成分として含有する殺菌剤
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JPWO2004106352A1 (ja) 2003-05-29 2006-07-20 大正製薬株式会社 アルドヘキソピラノース中間体の製造法
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
CA2529878C (en) 2003-06-20 2012-11-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
EP1679965A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
WO2005011592A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-o-glucosides
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
WO2005012242A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
EP1660509B1 (de) 2003-08-26 2009-02-04 Boehringer Ingelheim International GmbH Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
JP2005247834A (ja) 2004-02-04 2005-09-15 Taisho Pharmaceut Co Ltd ナトリウム依存性グルコース供輸送体２の活性阻害剤
CN1950389B (zh) 2004-03-04 2011-01-19 橘生药品工业株式会社 含氮稠环衍生物，含该衍生物的药物组合物，和其作为药物的用途
BRPI0508259A (pt) 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
PL381247A1 (pl) 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
JPWO2005095373A1 (ja) 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
WO2005095372A1 (ja) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
JPWO2006006496A1 (ja) 2004-07-08 2008-04-24 アステラス製薬株式会社 アズレン誘導体の製造方法及びその合成中間体
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MX2007000811A (es) 2004-07-21 2007-04-02 Kissei Pharmaceutical Inhibidor de avance de enfermedad atribuida a acumulacion anormal de grasa en el higado.
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja) 2004-09-27 2006-05-11 Taisho Pharmaceut Co Ltd Ｓｇｌｔ２の活性阻害剤
WO2006035796A1 (ja) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. １－（β－Ｄ－グリコピラノシル）－３－置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7750145B2 (en) 2004-11-18 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
ES2358342T3 (es) 2005-02-15 2011-05-09 Kissei Pharmaceutical Co., Ltd. Compuesto 1-sustituido-7-(beta-d-glicopiranosiloxi)(aza)indol y composición farmacéutica comprendiendo el mismo.
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
WO2006090577A1 (ja) 2005-02-24 2006-08-31 Mayekawa Mfg. Co., Ltd. ロース・ばら部の肋骨脱骨方法及び装置
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
CA2604333A1 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
JPWO2006115137A1 (ja) 2005-04-22 2008-12-18 キッセイ薬品工業株式会社 ２−アミノベンズイミダゾール誘導体及びその医薬用途
WO2006119038A1 (en) 2005-04-29 2006-11-09 Naturegen, Inc. Compositions and methods for controlling glucose uptake
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
GEP20115206B (en) 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
AR054871A1 (es) 2005-07-27 2007-07-25 Boehringer Ingelheim Int Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
US20070036874A1 (en) 2005-08-05 2007-02-15 Litao Zhong Compositions and methods for controlling glucose and lipid uptake from foods
WO2007025943A2 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2007029668A1 (ja) 2005-09-08 2007-03-15 National University Corporation Kanazawa University ソフトイオン化法のための誘導体化試薬
AU2006289093A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US20070099237A1 (en) 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
JP2009167104A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
EP1854806A1 (en) 2006-05-02 2007-11-14 MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thioglycosides as pharmaceutically active agents
JP2009167103A (ja) 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2076503B1 (en) 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound for the treatment of diabetes
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8115017B2 (en) 2006-06-29 2012-02-14 Taisho Pharmaceutical Co., Ltd C-phenyl 1-thioglucitol compound
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
JP2008050353A (ja) 2006-07-27 2008-03-06 Mitsubishi Tanabe Pharma Corp 医薬組成物
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
WO2008020011A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008034859A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AU2007307544A1 (en) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
DE102006048728A1 (de) 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
WO2008049923A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
CA2668623A1 (en) 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2007316613B2 (en) 2006-11-09 2013-11-28 Boehringer Ingelheim International Gmbh Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
UY30801A1 (es) 2006-12-18 2008-07-03 Smithkline Beecham Corp Compuestos calciliticos
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PT2183263E (pt) 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
AU2009286380B2 (en) * 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives

Also Published As

Publication number Publication date
SI2496583T1 (sl) 2015-02-27
US20150065565A1 (en) 2015-03-05
CA2777857A1 (en) 2011-05-05
AU2010310956A1 (en) 2012-06-07
JP5696156B2 (ja) 2015-04-08
AP3099A (en) 2015-01-31
ECSP12011946A (es) 2012-07-31
JP2013509393A (ja) 2013-03-14
AP2012006281A0 (en) 2012-06-30
GEP20146104B (en) 2014-05-27
EP2496583B1 (en) 2014-12-10
WO2011051864A1 (en) 2011-05-05
US9439902B2 (en) 2016-09-13
US20150065512A1 (en) 2015-03-05
PT2496583E (pt) 2015-01-14
EA021983B1 (ru) 2015-10-30
CA2777857C (en) 2014-12-02
US20130225487A1 (en) 2013-08-29
CR20120289A (es) 2012-09-26
DK2496583T3 (en) 2015-02-02
EP2496583A1 (en) 2012-09-12
KR101426180B1 (ko) 2014-07-31
RS53827B1 (sr) 2015-06-30
ES2527179T3 (es) 2015-01-21
PL2496583T3 (pl) 2015-04-30
HRP20150107T1 (xx) 2015-03-13
EA201290267A1 (ru) 2012-12-28
US9308204B2 (en) 2016-04-12
AU2010310956B2 (en) 2014-05-08
ZA201203486B (en) 2013-07-31
US20150065513A1 (en) 2015-03-05
US8669380B2 (en) 2014-03-11
NZ599945A (en) 2014-05-30
KR20120093321A (ko) 2012-08-22
US20120184486A1 (en) 2012-07-19
US9439901B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
ME02016B (me) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
JP2013509393A5 (me)
US6500838B2 (en) Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
JP2011521940A5 (me)
CN116710446B (zh) Glp-1r激动剂的晶型及其用途
JP2017519025A5 (me)
NZ542690A (en) Muscarinic M1 receptor agonists for pain management
RU2006133118A (ru) Средство для чрескожного введения никотина
KR20040044953A (ko) 요실금 치료를 위한, 무스카린 길항제와 선택된오피오이드와의 배합물
CA2685126C (en) Therapeutic or prophylactic agent for dyskinesia
EP3265466A1 (en) Peripheral-anticholinergic muscarinic agonist combination
JP2007500676A (ja) 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
NZ537197A (en) Use of nefopam for the treatment of nausea or emesis
AU700520B2 (en) NK-1 receptor antagonists for the treatment of cancer
US20190381039A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
AU2002327635B2 (en) Enhancement of learning and memory and treatment of amnesia
JP2022554230A5 (me)
AU2002327635A1 (en) Enhancement of learning and memory and treatment of amnesia
KR20220166393A (ko) 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도
RU2022100958A (ru) Комбинированная терапия агонистами gpr119 и ингибиторами dpp-4
AU2022366192A1 (en) Trpc6 inhibitory compounds for treating sepsis
HK40089377B (en) Crystal forms of glp-1r agonists and uses thereof
HK40089377A (en) Crystal forms of glp-1r agonists and uses thereof
RU2006120076A (ru) Способ лечения паразитарных болезней животных
RU2018101141A (ru) Композиции и способы ингибирования клеточной адгезии или направленности диагностических или терапевтических агентов к rgd связывающим сайтам